Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally
Biogen (NASDAQ:BIIB) and Stoke Therapeutics (NASDAQ:STOK) said on Tuesday they are collaborating to develop and commercialize ...
Biogen’s stock slides on soft guidance and a decline in sales of MS drugs
Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset below-consensus EPS outlook.